tiprankstipranks
Blurbs

Edgewise Therapeutics (EWTX) Gets a Hold Rating from Goldman Sachs

Goldman Sachs analyst Madhu Kumar maintained a Hold rating on Edgewise Therapeutics (EWTXResearch Report) today and set a price target of $5.00. The company’s shares closed last Tuesday at $6.52.

According to TipRanks.com, Kumar is a 5-star analyst with an average return of 17.3% and a 48.1% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Arrowhead Pharmaceuticals, and Iovance Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edgewise Therapeutics with a $5.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Edgewise Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $12.7 million. In comparison, last year the company had a GAAP net loss of $6.82 million.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EWTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Read More on EWTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed